EcoDrugPlus

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSOCUG00000010569
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSOCUG00000017322
Gene Symbol: ERBB3
3 Cross references
282 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSOCUG00000009790
Gene Symbol: ERBB4
2 Cross references
236 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSOCUG00000004829
Gene Symbol: ESR1
3 Cross references
210 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSOCUG00000005083
Gene Symbol: ESR2
2 Cross references
273 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSOCUG00000000984
Gene Symbol: ESRRG
3 Cross references
277 Possible Orthologues:

Exportin 1

Ensembl ID : ENSOCUG00000004986
Gene Symbol: XPO1
3 Cross references
304 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSOCUG00000033536
Gene Symbol: FDPS
2 Cross references
265 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSOCUG00000005160
Gene Symbol: FDFT1
3 Cross references
215 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSOCUG00000003441
Gene Symbol: FAAH
2 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSOCUG00000005115
Gene Symbol: FAP
2 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSOCUG00000000476
Gene Symbol: FGF2
2 Cross references
117 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).